Mizuho downgraded Exact Sciences(EXAS) to Neutral from Outperform with a price target of $105, up from $85. The firm cites Abbott’s (ABT) agreement to acquire Exact Sciences for $105 per share in cash for the downgrade. Mizuho sees minimal regulatory push-back to the deal and expects it to close on time by Q2.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Sets February 20, 2026 Virtual Meeting for Shareholder Vote on $105-per-Share Abbott Merger
- Abbott price target lowered to $152 from $157 at Goldman Sachs
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Exact Sciences downgraded to In Line from Outperform at Evercore ISI
- Exact Sciences Approves Executive Bonus Acceleration Amid Abbott Merger